For decades, the standard of care for obstructive sleep apnea (OSA) has been tethered to a rigid, metrics-driven gatekeeping policy. Under current Medicare guidelines, patients prescribed Continuous Positive Airway Pressure (CPAP) devices must demonstrate "compliance" within the first 90 days of treatment—defined as using the device for at least four hours per night on 70% of nights within a rolling 30-day window. Failure to meet these specific thresholds often results in the immediate cessation of insurance coverage, effectively forcing patients to forfeit their equipment.
However, a landmark study presented at the American Thoracic Society (ATS) 2026 International Conference is now challenging the scientific validity of this policy. By analyzing a massive dataset of over 132,000 patients, researchers have uncovered evidence that suggests the 90-day "compliance cliff" may be doing more harm than good, cutting off access to life-saving therapy for patients who simply require a longer adjustment period.
The Chronology of a Policy Crisis
The current Medicare criteria, which many private insurers have adopted as the gold standard for coverage, were established during an era when CPAP technology was significantly more cumbersome and data tracking was less granular. The policy was designed to ensure that equipment was not being paid for by taxpayers if it were destined to collect dust on a bedside table.
Over the last decade, however, sleep medicine has evolved. Modern CPAP devices are quieter, more comfortable, and integrated with sophisticated telemetry that allows for real-time monitoring. Despite these technological leaps, the policy remains stagnant.
The study, led by Dr. Dennis Hwang, a sleep and pulmonary physician at Kaiser Permanente Southern California, serves as a retrospective critique of this entrenched framework. By utilizing the Kaiser Permanente health system—which historically provides CPAP devices to patients regardless of their early-use metrics—researchers were able to observe what happens to "non-compliant" patients when they aren’t prematurely stripped of their access to therapy. The result was a clear longitudinal picture that contradicts the "all or nothing" logic currently governing the industry.
Supporting Data: Debunking the "Failure" Myth
The scale of the Kaiser Permanente study provides a robust rebuttal to the status quo. With a cohort of 132,000 patients, the researchers found that 51% of participants failed to meet the traditional 90-day Medicare criteria. Under standard insurance protocols, these patients would have been deemed "treatment failures" and their equipment would have been reclaimed.
However, the longitudinal data revealed a far more nuanced reality:
- Persistent Usage: More than one-third of the patients who initially missed the Medicare usage threshold were still actively using their CPAP devices one year later.
- The "Partial Success" Metric: Even among those who remained below the four-hour-per-night threshold, many were using their devices for two or more hours. Clinical literature has long established that even two hours of usage can yield significant symptomatic relief and cardiovascular health benefits for OSA patients.
- Adaptation Curves: The data demonstrates that the first three months are often a period of significant physiological and psychological adjustment. Many patients who struggle early on eventually "click" with the therapy, finding the right mask fit and pressure settings that allow them to incorporate the machine into their nightly routine long-term.
These findings suggest that early non-adherence is not a reliable predictor of long-term failure; rather, it is frequently a sign of a patient who needs more clinical support, not less.
Official Responses and Clinical Perspectives
The implications of this research are being felt across the sleep medicine community. Dr. Dennis Hwang, the lead author of the study, has been vocal about the disconnect between administrative policy and patient physiology.
"Our findings suggest clinicians and policymakers should not rely solely on Medicare-defined adherence, given its reliance on early CPAP use and an arbitrary four-hour threshold, when making long-term treatment decisions," Dr. Hwang stated in a press release following the conference. "Extending support and coverage beyond the first 90 days could help more patients achieve meaningful benefit."
Dr. Hwang emphasizes that the current system essentially penalizes the "slow learner." By framing treatment as a pass-fail test administered in the first quarter, the healthcare system may be inadvertently creating barriers for the very people who need help navigating the complexities of sleep apnea treatment.
The medical community has long acknowledged that mask intolerance and the psychological hurdle of wearing a device during sleep are significant challenges. Yet, the current policy provides little incentive for insurers to fund the specialized respiratory therapy coaching that might turn an early "non-compliant" patient into a long-term successful user. Instead, the current policy serves as a cost-containment measure that prioritizes short-term expenditure over long-term health outcomes.
Implications for Healthcare Policy and Patient Access
The shift suggested by the ATS 2026 findings could necessitate a total overhaul of how sleep apnea is managed by insurance providers. If the goal of healthcare is to maximize patient health—reducing the risk of hypertension, stroke, and daytime sleepiness—then the current 90-day mandate is arguably counterproductive.
1. From "Compliance" to "Engagement"
The industry is moving toward a shift in terminology. "Compliance" implies a passive patient following an order; "engagement" implies a collaborative process. If patients are not meeting the four-hour mark, the policy response should be a referral for additional support, not a revocation of coverage.
2. Evidence-Based Coverage
The researchers are already looking toward the next phase of their study: identifying which specific patient demographics are most likely to become long-term users despite early struggles. By developing predictive models, they hope to create coverage policies that are evidence-based rather than arbitrary. This could involve "extended trial periods" for patients who show promise but haven’t reached the threshold.
3. Economic Consequences
While insurers fear the cost of paying for devices that aren’t used, they must also consider the downstream costs of untreated OSA. The long-term health consequences of sleep apnea—ranging from increased traffic accidents due to daytime fatigue to chronic heart disease—cost the healthcare system billions annually. Providing an extra few months of coverage for a patient to adapt to their CPAP machine is a negligible expense compared to the lifetime cost of managing the systemic health issues caused by untreated apnea.
The Future of Sleep Medicine
The study presented at ATS 2026 is a clarion call for reform. It suggests that the rigid 90-day window is a relic of an era that lacked the capability to provide the nuanced, longitudinal care that modern sleep medicine demands.
As the research team moves forward with future studies, they hope to influence the Centers for Medicare & Medicaid Services (CMS) and private insurers to rethink their definitions of "adherence." The data is clear: forcing a patient to meet an arbitrary standard within an arbitrary timeframe does not equate to better health. It only equates to fewer people having access to the tools they need to breathe—and sleep—more effectively.
In conclusion, the path toward better sleep health lies in patience and persistence. By discarding the rigid metrics that currently define success in the sleep clinic, we can create a system that fosters long-term health, honors the realities of patient adaptation, and ensures that no one is left struggling simply because they needed a little more time to adjust to the life-changing power of CPAP therapy.
